228 Park Ave S
6 articles with Cambrian Biopharma
Private investors, governmental institutions and longtime life sciences investors provided funding to develop therapies for cancers, dermatological problems and acute ischemic strokes.
Oviva Therapeutics, a Cambrian BioPharma *PipeCo, announces Seed Financing and Exclusive License with Massachusetts General Hospital to Develop Therapeutics to Extend Healthspan in Women
Oviva Therapeutics, Inc., the women's health biotech company and a Cambrian Biopharma *PipeCo, announced an in-licensing agreement with Massachusetts General Hospital of a family of patents, as well as $11.5 million in Seed funding, to develop first-in-class therapeutics to improve healthspan – the period of life spent in good health - in women.
Cambrian Biopharma today announced a licensing agreement with Novartis to advance novel, selective compounds designed and characterized by Novartis to target the mechanistic target of rapamycin (mTOR) pathway.
10/27/2021While the volatility of the market has some shying away from going public, private investment dollars are still rolling in each week. Check out our top picks.
Cambrian Biopharma Closes $100 Million Series C to Advance Healthspan-boosting Therapeutics to the Clinic
Cambrian Biopharma, a multi-asset longevity biotech, announced the close of an oversubscribed Series C financing, which raised $100 million.
Cambrian Biopharma announced an oversubscribed $100 million Series C. The biotech aims to prevent age-related diseases and increase healthy lifespans.